Journal Article

Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective

Deal, Cheri L., Petriczko, Elżbieta, Storr, Helen L., Langham, Shirley, Dattani, Mehul T., Dalle Molle, Leo, Harvey, Jamie, Backeljauw, Philippe F., Polak, Michel, Andrews, Mary, Bang, Peter

2023

Overview

Background Severe primary insulin-like growth factor-I (IGF-I) deficiency (SPIGFD) is a rare growth disorder characterized by short stature (standard deviation score [SDS] ≤ 3.0), low circulating concentrations of IGF-I (SDS ≤ 3.0), and normal or elevated concentrations of growth hormone (GH). Laron syndrome is the best characterized form of SPIGFD, caused by a defect in the GH receptor ( GHR ) gene. However, awareness of SPIGFD remains low, and individuals living with SPIGFD continue to face challenges associated with diagnosis, treatment and care. Objective To gather perspectives on the key challenges for individuals and families living with SPIGFD through a multi-stakeholder approach. By highlighting critical gaps in the awareness, diagnosis, and management of SPIGFD, this report aims to provide recommendations to improve care for people affected by SPIGFD globally. Methods An international group of clinical experts, researchers, and patient and caregiver representatives from the SPIGFD community participated in a virtual, half-day meeting to discuss key unmet needs and opportunities to improve the care of people living with SPIGFD. Results As a rare disorder, limited awareness and understanding of SPIGFD amongst healthcare professionals (HCPs) poses significant challenges in the diagnosis and treatment of those affected. Patients often face difficulties associated with receiving a formal diagnosis, delayed treatment initiation and limited access to appropriate therapy. This has a considerable impact on the physical health and quality of life for patients, highlighting a need for more education and clearer guidance for HCPs. Support from patient advocacy groups is valuable in helping patients and their families to find appropriate care. However, there remains a need to better understand the burden that SPIGFD has on individuals beyond height, including the impact on physical, emotional, and social wellbeing. Conclusions To address the challenges faced by individuals and families affected by SPIGFD, greater awareness of SPIGFD is needed within the healthcare community, and a consensus on best practice in the care of individuals affected by this condition. Continued efforts are also needed at a global level to challenge existing perceptions around SPIGFD, and identify solutions that promote equitable access to appropriate care. Medical writing support was industry-sponsored.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Advocacy / Analysis / Caregivers / Diabetes therapy / Diagnosis / Endocrinology / Families & family life / Growth hormone insensitivity (GHI) / Growth hormones / Health aspects / Health care / Human Genetics / Insulin / Insulin-like growth factor 1 / Insulin-like growth factor I / Insulin-like growth factor-I (IGF-I) / Insulin-like growth factors / Laron syndrome / Medical diagnosis / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Methods / Mutation / Patient advocacy / Patient compliance / Patients / Pediatrics / Pharmacology/Toxicology / Quality of life / Rare diseases / Rare endocrinological diseases / Review / Severe primary IGF-I deficiency (SPIGFD) / Short stature / Somatotropin